Josephine A. Mauskopf

Josephine Mauskopf is a Distinguished Fellow, Health Economics in RTI Health Solutions, a business unit of RTI International. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs or vaccines for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, multiple sclerosis, bipolar disease, breast cancer, and HIV infection as well as for new vaccination programs.  She has estimated the impact of an antidepressant on work and social disability.

Dr. Mauskopf has also performed many strategic literature reviews that have been published in peer-reviewed journals, including reviews of cost of care for Alzheimer’s disease, cost of care for treatment-resistant depression, a review of the methods used to estimate the cost-effectiveness of vaccine programs using dynamic programming models, tiotropium for chronic obstructive pulmonary disease, and treatments for uterine fibroids. She also developed Markov models of disease progression for lung cancer and HIV infection and has developed simulation models of time spent in the operating and recovery rooms and of disease progression for HIV infection. Dr. Mauskopf has leveraged multi-criteria decision analysis (MCDA) to estimate the likelihood of reimbursement for products with different attributes and to estimate the impact of benefits and risks on drug prescribing decisions. Dr. Mauskopf was co-chair of two ISPOR Task Forces, one to develop guidelines for budget impact analysis and the other to develop guidelines for the economic evaluation of vaccination programs.

During her professional career, in addition to her experience at RTI, Dr. Mauskopf was Department Head of Economics Research at Burroughs Wellcome Co. and Director of Pharmacoeconomics Research for Anti-Virals and Anti-Infectives at Glaxo Wellcome Inc. She completed an 8-year term as Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality. She is currently an Associate Editor for the journals Medical Decision Making and Medical Decision Making – Policy and Practice. She received the ISPOR award for Excellence in Application of Pharmacoeconomics and Outcomes Research in 2006, the ISPOR Avedis Donabedian Lifetime Achievement Award in 2013, and in 2019 she received the ISPOR Marilyn Dix Smith Leadership Award.